Relation Therapeutics joins forces with AI-based research institute Mila for identification of therapeutic candidates for COVID-19

Relation Therapeutics joins forces with AI-based research institute Mila for identification of therapeutic candidates for COVID-19

The drug development firm, Relation Therapeutics, which uses machine learning technology, has announced a new initiative called the Project RE, to screen and identify combinations of repurposed drugs as a potential therapy for COVID-19. Project RE is co-led by the…

New study suggests patients with mild to moderate COVID-19 infection can continue angiotensin medications, dispels safety concerns

New study suggests patients with mild to moderate COVID-19 infection can continue angiotensin medications, dispels safety concerns

Patients diagnosed with health conditions are generally advised to take angiotensin-converting enzyme inhibitors (ACE) and angiotensin receptor blockers (ARBs) to regulate blood pressure and monitor heart conditions. Researchers faced conflicting experimental evidence regarding the impact of these angiotensin medications in…

Pfizer expects results of late-stage vaccine trials by October, says CEO Albert Bourla

Pfizer expects results of late-stage vaccine trials by October, says CEO Albert Bourla

Pharmaceutical giant Pfizer Inc. could have the results from the late-stage trials of the company’s COVID-19 vaccine candidate, CEO Albert Bourla announced during an online briefing that was sponsored by the drug industry consortium, International Federation of Pharmaceuticals Manufacturers &…

Oxford-AstraZeneca vaccine trials scheduled at PGIMER delayed over pending safety approvals

Oxford-AstraZeneca vaccine trials scheduled at PGIMER delayed over pending safety approvals

The Oxford-AstraZeneca coronavirus vaccine, which is called Covishield in India, is one of the most promising vaccine candidates against the novel COVID-19 illness. Covishield is currently underway in the clinical trials and will be produced by the Serum Institute of…